Peroxisome proliferator-activated receptor-γ agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution

Qiang Yao, Krzysztof Pawlaczyk, Ernesto Rodríguez Ayala, Malgorzata Kuzlan, Arkadiusz Styszynski, Andrzej Breborowicz, Olof Heimbürger, Jiaqi Qian, Peter Stenvinkel, Jonas Axelsson, Bengt Lindholm

Research output: Contribution to journalArticle

8 Scopus citations


Background: To evaluate if peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists have a potential protective effect on the peritoneum changes induced by bioincompatible peritoneal dialysis (PD) solution in vivo. Methods: Male Wistar rats were dialyzed three times daily for 28 days with 1.36% Dianeal® (two groups: with (D+R) or without (D) rosiglitazone) or 1.36% Physioneal® (two groups: with (P+R) or without (P) rosiglitazone). Peritoneal transport of fluid and small solutes was assessed. Nine rats that did not receive dialysis served as controls. Results: Significant morphological changes were found in the D group compared with controls. Additional use of rosiglitazone in the D+R group resulted in less morphological changes and expression of collagen I as well as an increased drainage volume. The expression of VEGF was inhibited by rosiglitazone while no apparent effect was found regarding TGF/Smad pathway. Conclusions: The addition of rosiglitazone to standard dialysis fluids can maintain the peritoneal morphology and increase ultrafiltration in a PD rat model.

Original languageEnglish (US)
Pages (from-to)575-582
Number of pages8
JournalBlood Purification
Issue number5-6
Publication statusPublished - Dec 1 2006



  • Biocompatible solution
  • Fibrosis
  • Peritoneal dialysis
  • Peroxisome proliferator-activated receptor-γ agonist

ASJC Scopus subject areas

  • Hematology
  • Nephrology

Cite this